Menu

An Overhaul for Human Research?

Proposed rules would streamline human research and strengthen protections for study subjects, according to the US government.

Jul 26, 2011
Tia Ghose

Vaccine trialFLICKR, US ARMY AFRICA

The US government is proposing a major overhaul of the rules that govern human subjects research, hoping to strengthen protections while eliminating red tape.

One proposed change would require any study conducted at an institution receiving government funding to abide by the human subject guidelines—even if an outside source such as a drug company pays for the study, The New York Times reports. Another measure would require consent from patients before their DNA or tissue is used in follow-up studies. Right now, tissue samples that aren’t linked to a person’s identity may be used without consent for later studies.

Other changes, such as allowing a single institutional review board to approve studies for multiple sites, are intended to reduce unnecessary regulatory delays. Currently, each site enrolling patients must go through a laborious approval process. The guidelines also suggest streamlining lengthy, confusing informed consent forms, ScienceInsider reports.

The current guidelines haven’t been updated since 1991. The public has 60 days to comment on the proposed rules.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.